You are here

  • Home
  • Archive
  • Volume 78, Issue 8
  • Response to: ‘Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities’ by Bossuyt et al

Article Text

Article menu

Download PDFPDF

Correspondence response
Response to: ‘Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities’ by Bossuyt et al
Free
  1. David S Pisetsky1,
  2. Diane M Spencer1,
  3. Peter E Lipsky2,
  4. Brad H Rovin3
  1. 1 Department of Medicine and Immunology, Duke University Medical Center and Medical Research Service, VA Medical Center, Durham, North Carolina, USA
  2. 2 RILITE Research Institute, Charlottesville, Virginia, USA
  3. 3 Division of Nephrology, The Ohio State University, Columbus, Ohio, USA
  1. Correspondence to Dr David S Pisetsky, Department of Medicine and Immunology, Duke University Medical Center, Durham, NC 27705, USA; david.pisetsky{at}duke.edu

https://doi.org/10.1136/annrheumdis-2018-213841

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We very much appreciate the comments of Willems et al 1 on our article on the variability of antinuclear antibody (ANA) testing for patients with established systemic lupus erythematosus (SLE).2 Others have provided their perspective on test variability.3–6 In their letter, Willems et al discuss the importance of antibody titre especially in the context of patient classification. In the new classification criteria under development, a positive ANA at a titre of 1:80 or higher is required.7 In …

    View Full Text

    Linked Articles